Why Prestige Brands Holdings Inc. Shares Soared

Prestige Brands announces its second acquisition this month and investors applaud. Can this momentum continue or is Prestige now overvalued?

Sean Williams
Sean Williams
Apr 25, 2014 at 2:04PM
Health Care

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Prestige Brands (NYSE:PBH), a developer and supplier of over-the-counter health care and household products, jumped as much as 20% after announcing the acquisition of privately held Insight Pharmaceuticals before the opening bell.

So what: Under the terms of the deal Prestige Brands will acquire Insight for $750 million in cash to expand its over-the-counter product line. The press release notes that Prestige will also acquire about $100 million in tax attributes which will partially offset its $750 million buyout price. Insight's products include Monistat, which is a yeast infection treatment, the EPT home pregnancy test, and a number of other feminine care products. This marks the second transaction this month for Prestige, which noted on April 15 that it was buying Hydralyte, an over-the-counter hydration therapy in Australia and New Zealand.

Now what: Although Prestige's press release was incredibly short and made no mention of whether or not this would reduce costs and be immediately accretive to earnings, I would have to assume that it'll be accretive to earnings fairly quickly. This is good news for shareholders because Prestige's organic growth had essentially stalled. While it's great to see the company being proactive and purchasing new products lines and creating different avenues of cash flow it still remains to be seen if it can translate this into organic growth a year or more from now. With that being said, I can't say I'm a huge fan of this stock following today's meteoric rise from a valuation basis, and I'll certainly be sticking to the sidelines.